Matthew Hoffman1, Dimitra Palioura1, Ioannis D Kyriazis1, Maria Cimini1, Rachit Badolia2, Sudarsan Rajan1, Erhe Gao1, Nikolas Nikolaidis3, P Christian Schulze4, Ira J Goldberg5, Raj Kishore1, Vincent W Yang6, Thomas D Bannister7, Agnieszka B Bialkowska6, Craig H Selzman8, Stavros G Drakos2, Konstantinos Drosatos1. 1. Center for Translational Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (M.H., D.P., I.D.K., C.M., S.R., E.G., R.K., K.D.). 2. Nora Eccles Harrison Cardiovascular Research and Training Institute, Division of Cardiovascular Medicine (S.G.D., R.B.), Salt Lake City, UT. 3. Department of Biological Science, Center for Applied Biotechnology Studies, and Center for Computational and Applied Mathematics, College of Natural Sciences and Mathematics, California State University Fullerton (N.N.). 4. Department of Internal Medicine, Division of Cardiology, Angiology, Intensive Medical Care, and Pneumology, University Hospital Jena, Germany (P.C.S.). 5. Division of Endocrinology, Diabetes and Metabolism, New York University School of Medicine (I.J.G.). 6. School of Medicine, Stony Brook University, NY (V.W.Y., A.B.). 7. The Scripps Research Institute, Jupiter, FL (T.D.B.). 8. Division of Cardiothoracic Surgery (C.H.S.), Salt Lake City, UT.
Abstract
BACKGROUND: We previously showed that cardiomyocyte Krϋppel-like factor (KLF) 5 regulates cardiac fatty acid oxidation. As heart failure has been associated with altered fatty acid oxidation, we investigated the role of cardiomyocyte KLF5 in lipid metabolism and pathophysiology of ischemic heart failure. METHODS: Using real-time polymerase chain reaction and Western blot, we investigated the KLF5 expression changes in a myocardial infarction (MI) mouse model and heart tissue from patients with ischemic heart failure. Using 2D echocardiography, we evaluated the effect of KLF5 inhibition after MI using pharmacological KLF5 inhibitor ML264 and mice with cardiomyocyte-specific KLF5 deletion (αMHC [α-myosin heavy chain]-KLF5-/-). We identified the involvement of KLF5 in regulating lipid metabolism and ceramide accumulation after MI using liquid chromatography-tandem mass spectrometry, and Western blot and real-time polymerase chain reaction analysis of ceramide metabolism-related genes. We lastly evaluated the effect of cardiomyocyte-specific KLF5 overexpression (αMHC-rtTA [reverse tetracycline-controlled transactivator]-KLF5) on cardiac function and ceramide metabolism, and rescued the phenotype using myriocin to inhibit ceramide biosynthesis. RESULTS: KLF5 mRNA and protein levels were higher in human ischemic heart failure samples and in rodent models at 24 hours, 2 weeks, and 4 weeks post-permanent left coronary artery ligation. αMHC-KLF5-/- mice and mice treated with ML264 had higher ejection fraction and lower ventricular volume and heart weight after MI. Lipidomic analysis showed that αMHC-KLF5-/- mice with MI had lower myocardial ceramide levels compared with littermate control mice with MI, although basal ceramide content of αMHC-KLF5-/- mice was not different in control mice. KLF5 ablation suppressed the expression of SPTLC1 and SPTLC2 (serine palmitoyltransferase [SPT] long-chain base subunit ()1 2, respectively), which regulate de novo ceramide biosynthesis. We confirmed our previous findings that myocardial SPTLC1 and SPTLC2 levels are increased in heart failure patients. Consistently, αMHC-rtTA-KLF5 mice showed increased SPTLC1 and SPTLC2 expression, higher myocardial ceramide levels, and systolic dysfunction beginning 2 weeks after KLF5 induction. Treatment of αMHC-rtTA-KLF5 mice with myriocin that inhibits SPT, suppressed myocardial ceramide levels and alleviated systolic dysfunction. CONCLUSIONS: KLF5 is induced during the development of ischemic heart failure in humans and mice and stimulates ceramide biosynthesis. Genetic or pharmacological inhibition of KLF5 in mice with MI prevents ceramide accumulation, alleviates eccentric remodeling, and increases ejection fraction. Thus, KLF5 emerges as a novel therapeutic target for the treatment of ischemic heart failure.
BACKGROUND: We previously showed that cardiomyocyte Krϋppel-like factor (KLF) 5 regulates cardiac fatty acid oxidation. As heart failure has been associated with altered fatty acid oxidation, we investigated the role of cardiomyocyte KLF5 in lipid metabolism and pathophysiology of ischemic heart failure. METHODS: Using real-time polymerase chain reaction and Western blot, we investigated the KLF5 expression changes in a myocardial infarction (MI) mouse model and heart tissue from patients with ischemic heart failure. Using 2D echocardiography, we evaluated the effect of KLF5 inhibition after MI using pharmacological KLF5 inhibitor ML264 and mice with cardiomyocyte-specific KLF5 deletion (αMHC [α-myosin heavy chain]-KLF5-/-). We identified the involvement of KLF5 in regulating lipid metabolism and ceramide accumulation after MI using liquid chromatography-tandem mass spectrometry, and Western blot and real-time polymerase chain reaction analysis of ceramide metabolism-related genes. We lastly evaluated the effect of cardiomyocyte-specific KLF5 overexpression (αMHC-rtTA [reverse tetracycline-controlled transactivator]-KLF5) on cardiac function and ceramide metabolism, and rescued the phenotype using myriocin to inhibit ceramide biosynthesis. RESULTS: KLF5 mRNA and protein levels were higher in human ischemic heart failure samples and in rodent models at 24 hours, 2 weeks, and 4 weeks post-permanent left coronary artery ligation. αMHC-KLF5-/- mice and mice treated with ML264 had higher ejection fraction and lower ventricular volume and heart weight after MI. Lipidomic analysis showed that αMHC-KLF5-/- mice with MI had lower myocardial ceramide levels compared with littermate control mice with MI, although basal ceramide content of αMHC-KLF5-/- mice was not different in control mice. KLF5 ablation suppressed the expression of SPTLC1 and SPTLC2 (serine palmitoyltransferase [SPT] long-chain base subunit ()1 2, respectively), which regulate de novo ceramide biosynthesis. We confirmed our previous findings that myocardial SPTLC1 and SPTLC2 levels are increased in heart failure patients. Consistently, αMHC-rtTA-KLF5 mice showed increased SPTLC1 and SPTLC2 expression, higher myocardial ceramide levels, and systolic dysfunction beginning 2 weeks after KLF5 induction. Treatment of αMHC-rtTA-KLF5 mice with myriocin that inhibits SPT, suppressed myocardial ceramide levels and alleviated systolic dysfunction. CONCLUSIONS: KLF5 is induced during the development of ischemic heart failure in humans and mice and stimulates ceramide biosynthesis. Genetic or pharmacological inhibition of KLF5 in mice with MI prevents ceramide accumulation, alleviates eccentric remodeling, and increases ejection fraction. Thus, KLF5 emerges as a novel therapeutic target for the treatment of ischemic heart failure.
Authors: Liyan Zhang; John R Ussher; Tatsujiro Oka; Virgilio J J Cadete; Cory Wagg; Gary D Lopaschuk Journal: Cardiovasc Res Date: 2010-08-20 Impact factor: 10.787
Authors: Ainara Ruiz de Sabando; Chao Wang; Yuanjun He; Mónica García-Barros; Julie Kim; Kenneth R Shroyer; Thomas D Bannister; Vincent W Yang; Agnieszka B Bialkowska Journal: Mol Cancer Ther Date: 2015-11-30 Impact factor: 6.261
Authors: Li Liu; Chad M Trent; Xiang Fang; Ni-Huiping Son; HongFeng Jiang; William S Blaner; Yunying Hu; Yu-Xin Yin; Robert V Farese; Shunichi Homma; Andrew V Turnbull; Jan W Eriksson; Shi-Lian Hu; Henry N Ginsberg; Li-Shin Huang; Ira J Goldberg Journal: J Biol Chem Date: 2014-08-25 Impact factor: 5.157
Authors: M Verheij; R Bose; X H Lin; B Yao; W D Jarvis; S Grant; M J Birrer; E Szabo; L I Zon; J M Kyriakis; A Haimovitz-Friedman; Z Fuks; R N Kolesnick Journal: Nature Date: 1996-03-07 Impact factor: 49.962
Authors: Lauren K Park; Valene Garr Barry; Juan Hong; John Heebink; Rajan Sah; Linda R Peterson Journal: Curr Opin Lipidol Date: 2022-02-01 Impact factor: 4.616
Authors: Alberto Ouro; Clara Correa-Paz; Elena Maqueda; Antía Custodia; Marta Aramburu-Núñez; Daniel Romaus-Sanjurjo; Adrián Posado-Fernández; María Candamo-Lourido; Maria Luz Alonso-Alonso; Pablo Hervella; Ramón Iglesias-Rey; José Castillo; Francisco Campos; Tomás Sobrino Journal: Front Mol Biosci Date: 2022-04-20